U.S. Markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.8099%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3922
    -0.0091 (-0.6460%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.3012%)
     
  • BTC-USD

    44,408.79
    -3,014.98 (-6.36%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Global Blood Seeks Label Expansion of Oxbryta in Kids With SCD

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Global Blood Therapeutics, Inc. GBT announced plans to expand the label of Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in children aged 4 to 11 years, following a Type B meeting with the FDA.

In November 2019, the FDA approved Oxbryta as an oral, once-daily treatment for SCD in patients aged 12 years or above. Following this, the drug became the first and only therapy that directly inhibits sickle hemoglobin polymerization, a major cause for SCD. SCD is a chronic, inherited blood disorder that affects hemoglobin levels.

Global Blood plans to submit a New Drug Application (NDA) for Oxbryta, which will include a new, age-appropriate formulation, for the treatment of SCD in children 4 to 11 years under the FDA’s accelerated approval pathway. The NDA will include clinical data from the ongoing phase IIa HOPE-KIDS 1 study.

Shares of Global Blood have declined 17.2% so far this year against the industry’s growth of 7.9%.

 

The company has another pipeline candidate, inclacumab, which is a novel fully human monoclonal antibody against P-selectin, in its portfolio. The drug is being developed as a treatment for vaso-occlusive crises (“VOC”) in patients with SCD. The company is developing inclacumab with drug giant Roche Holding AG RHHBY.

Last year, the FDA also approved Novartis’ NVS Adakveo (crizanlizumab) to lower the frequency of VOCs or pain crises in patients with SCD, aged 16 years or above. bluebird bio BLUE is also developing LentiGlobin for the treatment of VOC in patients with SCD.

 

Global Blood Therapeutics, Inc. Price

 

Global Blood Therapeutics, Inc. Price
Global Blood Therapeutics, Inc. Price

 

Global Blood Therapeutics, Inc. price | Global Blood Therapeutics, Inc. Quote

Zacks Rank

Global Blood currently has a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Roche Holding AG (RHHBY) : Free Stock Analysis Report
 
Novartis AG (NVS) : Free Stock Analysis Report
 
bluebird bio, Inc. (BLUE) : Free Stock Analysis Report
 
Global Blood Therapeutics, Inc. (GBT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.